RIPK3 and cancer: A previous report showed that deletion of RIPK3 led to reduced expression of the programmed death-ligand 1 (PD–L1) in macrophages as well as increased abundance of B cells and T cells and decreased abundance of myeloid-derived suppressor cells and tumor-associated macrophages [14], suggesting that the suppression of necroptosis by CHIP augmentation might help overcome the immune evasion of tumor cells, an important hallmark of cancer [34].